Prostate cancer and prostate-specific antigen (PSA) screening in Austria

Area of Science:

• Urology
• Public Health
• Epidemiology

Background:

• Prostate-specific antigen (PSA) testing for prostate cancer has widespread application but its effect on mortality remains controversial.
• Austria provides a uniform cohort for studying PSA testing's impact due to equal healthcare access.

Purpose of the Study:

• To examine age-specific prostate cancer mortality trends in Austria before and after the introduction of PSA testing.
• To determine if PSA screening reduces prostate cancer mortality in a uniform population.

Main Methods:

• Analysis of prostate cancer mortality data from 1970-2002 across Austria's 9 federal states.
• Application of join-point regression models to identify mortality trend changes in age groups 50-89.
• Separate analysis for Tyrol (mass screening project from 1993) and the rest of Austria (widespread PSA testing from 1989).

Main Results:

• No significant reduction in prostate cancer mortality observed in age groups 50-59, 60-69, and 80-89 years after PSA testing introduction.
• A significant decrease in mortality was observed in the 70-79 age group, but join points predate PSA testing availability.
• The observed mortality decrease in the 70-79 group cannot be attributed to PSA testing.

Conclusions:

• PSA screening does not appear to reduce prostate cancer mortality in a uniform cohort with equal healthcare access.
• Longer follow-up periods may be necessary to detect potential trends due to the long lead-time of prostate cancer.